Michael Snyder, PhD is an American genomicist, chair of genetics and director of genomics and personalized medicine at Stanford University, and the former director of the Yale Center for genomics and proteomics. He was elected to the American Academy of Arts and Sciences in 2015. During his tenure as chair of the department at Stanford, U.S. News & World Report has ranked Stanford University first or tied for first in genetics, genomics and bioinformatics under his leadership.

Snyder Lab was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks.

Snyder has co-founded companies in genetics, genomics, and personalized medicine, including Personalis, a company that develops software to interpret genomes after sequencing; January AI, a health startup; Protometrix; Affomix; and Q Bio.

Dr. Snyder received his PhD training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. Snyder has been a principal investigator of the ENCODE project since its inception in 2003, co-director of the CIRM Center for Stem Cell Genomics and director of the Center for Genome of Gene Regulation.